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Introduction
In mammals, DNA methylation is crucially involved in control-
ling gene expression, cell differentiation, silencing of trans-
posable elements, X inactivation, imprinting, and neoplastic 
transformation (Bird, 2002; Baylin and Ohm, 2006). DNA 
methylation patterns are established and maintained by three 
major DNA methyltransferases (DNMTs): DNMT1, DNMT3A, 
and DNMT3B. DNMT1 is the only mammalian DNMT that has 
a preference for hemimethylated CpG sites (Bestor and Ingram, 
1983; Pradhan et al., 1999) and localizes at both replication foci 
and repair sites because of its interaction with the proliferat-
ing cell nuclear antigen (PCNA; Leonhardt et al., 1992; Chuang 
et al., 1997; Margot et al., 2001; Easwaran et al., 2004; 
  Mortusewicz et al., 2005).
As a result of these observations and data from genetic 
manipulations in the mouse, DNMT1 is thought to be the major 
enzyme responsible for postreplicative maintenance of DNA 
methylation. Homozygous null deletions of mouse dnmt1 are 
lethal early in development and result in an 80% reduction 
of global genomic methylation in embryonic stem cells and 
embryos (Lei et al., 1996). These and other studies also 
showed  that despite growing normally, dnmt1
−/− embryonic 
stem cells have reduced differentiation potential both in vivo 
and in vitro (Gaudet et al., 1998; Jackson et al., 2004). Later 
work using conditional deletion demonstrated that Dnmt1 is 
  indispensable for the survival of differentiated cells (Jackson-
Grusby et al., 2001).
An equivalent role of DNMT1 in human cells was ques-
tioned by the homozygous deletion of exons 3–5 of the DNMT1 
gene in HCT116 colorectal carcinoma cells (Rhee et al., 2000). 
This deletion encompasses the sequence encoding the PCNA-
binding domain (PBD) of DNMT1 and leaves the next exon out 
of frame. Thus, it was expected that this deletion would elimi-
nate DNMT1 maintenance activity and cause a dramatic drop in 
genomic methylation levels. Surprisingly, HCT116 cells bear-
ing this deletion (referred to here as MT1 knockout [KO] cells) 
showed only a 20% reduction of global genomic methylation 
levels and nearly no loss of methylation at CpG islands. The 
  issue was further complicated by studies in which DNMT1 
levels were knocked down by RNAi in human tumor cell lines 
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  D
NA methylation plays a central role in the epigen-
etic regulation of gene expression in vertebrates. 
Genetic and biochemical data indicated that DNA 
methyltransferase 1 (Dnmt1) is indispensable for the main-
tenance of DNA methylation patterns in mice, but target-
ing of the DNMT1 locus in human HCT116 tumor cells 
had only minor effects on genomic methylation and cell 
viability. In this study, we identiﬁ  ed an alternative splicing 
in these cells that bypasses the disrupting selective marker 
and results in a catalytically active DNMT1 protein lack-
ing the proliferating cell nuclear antigen–binding domain 
required for association with the replication machinery. 
Using a mechanism-based trapping assay, we show 
that this truncated DNMT1 protein displays only twofold 
reduced postreplicative DNA   methylation maintenance 
activity in vivo. RNA interference–mediated knockdown of 
this truncated DNMT1   results in global genomic hypo-
methylation and cell death. These results indicate that 
DNMT1 is essential in mouse and human cells, but direct 
coupling of the   replication of genetic and epigenetic 
  information is not strictly required.
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(Leu et al., 2003; Robert et al., 2003; Suzuki et al., 2004). In 
these studies, a drastic decrease of methylation at CpG islands 
was observed, including a study using HCT116 cells (Leu et al., 
2003; Robert et al., 2003; Suzuki et al., 2004). At the same time, 
both the transient and stable knockdown of DNMT1 in HCT116 
cells seemed to have only a minor effect on methylation levels 
similar to those observed in MT1KO cells (Ting et al., 2004). 
Simultaneous KO of DNMT1 and DNMT3B in HCT116 cells 
(double KO [DKO] cells) resulted in a dramatic reduction of 
genomic methylation levels, suggesting a cooperative effect of 
DNMT1 and DNMT3B on the maintenance of DNA methyl-
ation (Rhee et al., 2002).
Interestingly, the combination of hypomorphic and null 
alleles in the mouse showed that animals expressing  20% of 
Dnmt1 wild-type (wt) levels are phenotypically inconspicuous 
and have normal levels of DNA methylation, whereas mice 
expressing  10% of Dnmt1 wt levels show severe hypomethy-
lation, are runted, and develop aggressive T cell lymphomas 
(Gaudet et al., 2003). Thus, there seems to be a threshold to the 
amount of Dnmt1 necessary for the maintenance of genomic 
methylation levels. This threshold amount of 10–20% roughly 
corresponds to the knockdown levels routinely achieved by 
RNAi and is hard to detect. Moreover, KO strategies may par-
tially be frustrated by alternative splicing yielding biologically 
active proteins, albeit at low levels. Indeed, the fi  rst attempt to 
knock out Dnmt1 in mice eliminated only part of exon 4 and 
lead to a partial loss of function as a result of alternative splicing 
and weak expression of a truncated form of Dnmt1 (Li et al., 
1992, 1993; Lei et al., 1996).
We carefully revisited DNMT1 expression in MT1KO and 
DKO cell lines at the RNA and protein levels. Using RT-PCR 
and a newly developed antibody, we found that alternative splic-
ing occurs in MT1KO and DKO cell lines that bypasses the KO 
cassette and allows the expression of a DNMT1 variant lacking 
the PBD. We show that this truncated variant is enzymatically 
active in vitro and in vivo and that its levels are crucial for the 
maintenance of global genomic methylation and cell survival.
Results and discussion
MT1KO and DKO cells express 
an internally deleted DNMT1 variant
We fi rst checked for the presence of DNMT1 transcripts in 
MT1KO and DKO cells. Northern blot analysis showed that 
MT1KO cells expressed low levels of an mRNA species with 
a slightly lower molecular weight than full-length DNMT1 
mRNA (Fig. 1 A). Consistently, reverse transcription followed 
by PCR amplifi  cation revealed the presence of DNMT1 mRNA 
species in parental HCT116 cells and DNMT KO derivatives 
(Fig. 1 B). A primer pair spanning exons 32–35 (corresponding 
to sequence coding for the catalytic domain) yielded different 
amounts of a specifi  c PCR fragment in parental, MT1KO, and 
DKO cells. A second primer pair spanning exons 1–15 and in-
cluding the region targeted for deletion (exons 3–5; Fig. 1 C) 
produced fragments with different sizes in parental and MT1KO 
cells, whereas no product was detectable in DKO cells. How-
ever, reamplifi  cation of these PCR reactions with a nested set of 
primers located in exons 2 and 10 produced the same two frag-
ments for MT1KO and DKO cells. Direct sequencing revealed 
that these fragments represent alternative splicing events, spec-
ifi  cally from the precise joining of exon 2 with either exon 7 
(smaller fragment) or exon 6 (larger fragment; Fig. 1 C). Splic-
ing from exons 2–7 does not alter the reading frame and would 
result in a DNMT1 protein with an internal deletion spanning 
part of the DMAP1 interaction domain (Rountree et al., 2000) 
and PBD. In contrast, exons 2 and 6 are not in frame, and their 
joining results in a reading frame terminating after 30 nt in exon 6 
(Fig. 1 C).
The same nested PCR approach with RNA from parental 
HCT116 cells produced three fragments. Direct sequencing 
showed that the smallest of these fragments corresponds to the 
transcript encoding the major DNMT1 somatic isoform, that the 
medium-sized fragment corresponds to the DNMT1b transcript 
isoform, which includes an additional 48-bp exon between 
  exons 4 and 5 (exon 4a; Fig. 1 C; Hsu et al., 1999; Bonfi  ls et al., 
2000), and that the largest fragment represents heteroduplex 
molecules of these two isoforms generated during the PCR 
  reaction. These results indicate that the alternative splicing is 
caused by genomic alterations of the DNMT1 KO allele.
To verify whether the detected alternatively spliced 
mRNAs are actually translated in vivo, we subjected whole cell 
extracts from parental, MT1KO, and DKO cell lines to Western 
blotting with a new monoclonal antibody against DNMT1 
(Fig. 1 D). A major band of  180 kD was detected in parental 
HCT116 cells, corresponding to the expected size of full-length 
DNMT1. In contrast, a single band with an approximate mole-
cular mass of 160 kD was detected in MT1KO and DKO cells. 
This size fi  ts the predicted molecular weight of the exons 2–7 
splicing isoform. Quantifi  cation after normalization with an 
antibody to lamin B showed that the relative abundance of the 
variant DNMT1 protein expressed in MT1KO and DKO cells 
with respect to the wt DNMT1 in parental HCT116 cells is at 
most 17 and 11%, respectively (Fig. 1 D). We conclude that 
MT1KO and DKO cell lines express decreased amounts of a 
mutant DNMT1 protein that originates from an alternative 
splicing event bypassing the deletion of exons 3–5. This mutant, 
which we hereafter refer to as DNMT1
∆E3–6, lacks part of the 
DMAP1 interaction domain and PBD.
DNMT1
𝖫𝖬3–6 is catalytically active both 
in vitro and in vivo and does not interact 
with PCNA
Next, we tested whether DNMT1
∆E3–6 is a functional methyl-
transferase. To this aim, we fi  rst transfected HEK293T cells 
with expression constructs for either human wt DNMT1, hu-
man DNMT1
∆Ε3–6, mouse Dnmt1 lacking the PBD, or mouse 
Dnmt1
C1229W all fused to GFP. In the latter construct, the cyste-
ine responsible for the transient formation of a covalent bond 
with the C5 position of the cytosine ring during the methyl-
ation reaction is replaced by tryptophan, resulting in a catalyti-
cally inactive enzyme (Schermelleh et al., 2005). Extracts were 
made from the transfected cells, and the respective GFP fusion 
proteins were immunopurifi  ed and tested for their methyltrans-
ferase activity in vitro. Except for GFP-Dnmt1
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as expected, had no substantial catalytic activity, all GFP-
fused enzymes showed very similar levels of methyltransferase 
activity (Fig. 2 A). This result shows that DNMT1
∆E3–6 is 
catalytically active in vitro. Importantly, GFP-DNMT1
∆E3–6 
that was transiently expressed in human cells localized to the 
nucleus (Fig. 2 C), which is consistent with the identifi  cation 
of multiple functional NLSs in mouse Dnmt1 (Cardoso and 
Leonhardt, 1999). This opened the possibility that the resid-
ual DNMT1
∆E3–6 could contribute to maintenance of the rela-
tively high genomic methylation levels in MT1KO cells. As 
the deletion in DNMT1
∆E3–6 eliminates the PBD, we checked 
whether GFP-DNMT1
∆E3–6 is still capable of interacting with 
PCNA. Endogenous PCNA coimmunoprecipitated with GFP-
DNMT1
wt expressed in HEK293T cells but not with GFP-
DNMT1
∆E3–6 (Fig. 2 B).
To test whether DNMT1
∆E3–6 is catalytically functional 
in vivo, we used a recently developed trapping assay (Scher-
melleh et al., 2005). HeLa cells were cotransfected with expression 
constructs for RFP-PCNA and either GFP-DNMT1
wt or GFP-
DNMT1
∆E3–6. 24 h after transfection, cells were incubated in the 
presence of 5-aza-deoxycytidine (5-aza-dC). During replica-
tion, this cytosine analogue is incorporated into newly synthe-
sized DNA. When DNMT1 engages in the methylation of 
5-aza-dC, a covalent complex is formed that cannot be resolved. 
As a consequence, DNMT1 is immobilized (trapped) at these 
sites. The trapping rate can be measured by FRAP as a time-
  dependent decrease of the mobile fraction of GFP-DNMT1 fu-
sions and refl  ects their enzymatic activity in vivo. In contrast to 
GFP-DNMT1
wt, GFP-DNMT1
∆E3–6 did not accumulate at repli-
cation foci during early to mid S phase (Fig. 2 C). This is con-
sistent with our coimmunoprecipitation results and data obtained 
with a mouse Dnmt1 mutant lacking the PBD (Easwaran et al., 
2004). However, upon the addition of 5-aza-dC, a time-dependent 
focal accumulation of GFP- DNMT1
∆E3–6 was observed. FRAP 
analysis revealed that GFP-DNMT1
∆E3–6 is trapped with only an 
approximately twofold lower effi  ciency than GFP-DNMT1
wt 
Figure 1.  DNMT1
−/− (MT1KO) and DNMT1
−/−;
DNMT3B
−/− (DKO) HCT116 cell lines express 
an internally deleted DNMT1 variant. 
(A) Northern blot analysis of HCT116 cell lines, 
including parental cells (+/+), two independent 
DNMT1
+/− clones, and one DNMT1
−/− clone 
(MT1KO). The blot was hybridized with a 
DNMT1 cDNA probe and a glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) probe as 
a loading control. The positions of the two tran-
scripts and molecular weight markers are indi-
cated. (B) RT-PCR analysis of parental (WT), 
DNMT1
−/− (MT1KO), and DNMT1
−/−;
DNMT3B
−/− (DKO) HCT116 cells. The ampli-
ﬁ   ed regions are indicated at the bottom of 
each panel. In the left panel, the arrowhead in-
dicates the speciﬁ  c PCR fragment, and the as-
terisk indicates an unspeciﬁ  c product. The right 
panel shows a nested PCR, where PCR pro-
ducts shown in the middle panel were used as 
templates. The two alternative splice forms ex-
pressed in MT1KO and DKO cells (right) and 
the positions of molecular weight markers are 
indicated. (C) Schematic drawing of the wt 
(top) and targeted DNMT1 alleles (middle) and 
alternatively spliced transcripts from the latter 
allele (bottom). Exons are shown as open rect-
angles (numbered on top) and are drawn to 
scale, whereas noncoding sequences are 
shown as lines and are not in scale. Sequences 
coding for major peptide domains are shown 
in different shades of gray, and their names are 
reported at the bottom. The positions of primers 
used for RT-PCR, translational start (ATG) co-
dons, and termination (STOP) codons are indi-
cated. (D) Western blot analysis of parental 
HCT116 cells and DNMT KO derivatives with 
antibodies to DNMT1 and lamin B1 (as a load-
ing control). The molecular mass of major 
bands is indicated. The 170-kD band detected 
with the anti-DNMT1 antibody in the parental 
cells lane has a higher molecular mass than the 
band detected in MT1KO and DKO lanes and 
likely represents a DNMT1 degradation pro-
duct. The percentages of normalized signal lev-
els from the DNMT1 variant in MT1KO and 
DKO cells with respect to wt DNMT1 levels in 
HCT116 cells (100%) are shown at the bottom 
of the corresponding lanes.JCB • VOLUME 176 • NUMBER 5 • 2007  568
(Fig. 2, C and D). These data strongly suggest that the 
DNMT1
∆E3–6 enzyme expressed in MT1KO and DKO cells is 
fully catalytically active, localizes to the nucleus, and is capable 
of postreplicative methylation maintenance despite the loss of 
interaction with PCNA.
The level of DNMT1
𝖫E3–6 in MT1KO cells 
is critical for cell survival and maintenance 
of global genomic methylation
We then sought to establish the contribution of DNMT1
∆E3–6 to 
the maintenance of genomic methylation levels in MT1KO 
cells. To this aim, we knocked down DNMT1
∆E3–6 by RNAi for 
a prolonged period of time and analyzed global genomic methy-
lation levels (Fig. 3). At each collection point, a relatively mod-
est but substantial decrease in DNMT1
∆E3–6 protein levels was 
achieved (Fig. 3 A). Progressively fewer cells were found in 
cultures treated with DNMT1 siRNA with respect to cultures 
treated with control siRNA (Fig. 3 B). Microscopic inspection 
of cultures after 8 and 12 d of treatment with DNMT1 siRNA 
revealed large numbers of dead cells and cells with very long 
and thin cytoplasmic protrusions, whereas cells treated with 
control siRNA exhibited a normal morphology and death rate 
(Fig. 3 C). Interestingly, both of these phenotypes are reminis-
cent of the highly hypomethylated DKO cells. Global genomic 
Figure 2.  GFP-DNMT1
𝖫E3–6 is catalytically 
active in vitro and is capable of postreplicative 
DNA methylation in vivo. (A) In vitro DNMT as-
say of GFP-DNMT1 fusion variants transiently 
expressed in HEK293T cells and immunopuri-
ﬁ  ed with an anti-GFP antibody. (B) Coimmuno-
precipitation of endogenous PCNA with either 
GFP-DNMT1
wt or GFP-DNMT1
∆E3–6 expressed 
in HEK293T cells. Input (I), ﬂ   ow through (F), 
and bound (B) fractions are shown; 5% of in-
put and ﬂ  ow through fractions with respect to 
bound fractions was loaded. The molecular 
masses of the two GFP fusions are indicated on 
the right. (C and D) Trapping assay for GFP-
DNMT1
wt and GFP-DNMT1
∆E3–6 transiently ex-
pressed in HeLa cells. (C) Images on the left 
show cells in early S phase according to the 
RFP-PCNA pattern and expressing the indi-
cated GFP-DNMT1 variant. The distribution of 
ﬂ  uorescent fusions is shown before and at indi-
cated time points after the addition of 30 μM 
5-aza-dC. Regions targeted by photobleaching 
are indicated by boxes and are shown mag-
niﬁ   ed at the bottom before and 0.3 (ﬁ   rst 
postbleaching time point) and 20 s after 
bleaching. Bars, 5 μm. Plots on the right show 
FRAP curves of GFP fusions at targeted regions 
before and at indicated time points after the 
addition of 5-aza-dC from the corresponding 
cells shown on the left. (D) Trapping assays for 
GFP-DNMT1
wt or GFP-DNMT1
∆E3–6 were per-
formed as in C on three cells for each con-
struct, and the estimated immobilized fractions 
were plotted with respect to the time of incuba-
tion with 5-aza-dC.MAINTENANCE OF DNA METHYLATION IN HUMAN CELLS • SPADA ET AL. 569
methylation was assayed by restriction with the endonuclease 
McrBC, which selectively digests methylated sequences, and 
by HPLC analysis (Fig. 3, D and E). Progressively lower geno-
mic methylation was detected from days 4 to 12 of treatment 
with DNMT1 siRNA, with cells treated for 8 and 12 d retaining 
only   10% of the methylated cytosines present in parental 
HCT116 cells, which is similar to the level found in DKO cells. 
Interestingly, the levels of DNMT3B remained unaffected until 
day 8 of RNAi treatment when global genomic methylation was 
already drastically decreased (Fig. 3, A, D, and E). A slight 
  reduction of DNMT3B levels was observed only after 12 d of 
RNAi treatment and is likely caused by secondary effects. Thus, 
a prolonged reduction of DNMT1
∆E3–6 levels, although moderate, 
caused a drastic decrease of genomic methylation in the presence 
of normal levels of DNMT3B.
These results indicate that the residual level of the DNMT1 
mutant present in MT1KO cells provides most of the methyl-
transferase activity responsible for maintaining relatively high 
methylation levels in this cell line. Interestingly, DKO cells ex-
press a similarly reduced amount of DNMT1
∆E3–6 (Fig. 1 D), 
which could explain their very low level of DNA methylation. 
Thus, the situation revealed here for the human MT1KO and 
DKO cell lines is reminiscent of transgenic mice bearing 
  hypomorphic and null dnmt1 alleles. Although homozygotes 
for the hypomorphic allele were phenotypically normal and 
showed nearly no molecular alterations, the combination of 
Figure 3.  Prolonged knockdown of DNMT1
𝖫𝖬3–6 in 
MT1KO cells leads to genomic demethylation and cell 
death. Equal numbers of MT1KO cells were plated 
and transfected with either DNMT1 or control siRNA 
the next day (day 0) and every second day for 12 d. 
On days 2, 4, 8, and 12, cells were harvested, ali-
quots were collected for protein extracts and DNA iso-
lation, and, except for day 12, equal numbers were 
replated. (A) Levels of DNMT1
∆Ε3–6 and DNMT3B 
were analyzed by Western blotting of whole cell ex-
tracts collected at the indicated days of siRNA treat-
ment. Detection of β-actin was used to control for 
loading. (B) Cell numbers were plotted taking into 
  consideration the splitting factor at each passage. 
(C) Phase-contrast images of MT1KO cultures treated 
with either control (left) or DNMT1 (middle) siRNA for 
12 d and an image of DKO cells (right). Arrows point 
to dead cells, and arrowheads point to cells with thin 
and extended cytoplasmic protrusions that are present 
only in MT1KO cells treated with DNMT1 siRNA and 
in DKO cells. Bars, 50 μm. (D and E) Assays for the 
determination of global genomic methylation levels 
from the indicated cell lines and treatments. (D) Geno-
mic DNA was digested with the McrBC endonuclease, 
which selectively recognizes methylated sequences. 
The top panel shows electrophoretic separation of the 
digests. Progressive demethylation in cells treated with 
DNMT1 siRNA is indicated by the increasingly similar 
patterns between mock digestions (−) and samples in-
cubated with the enzyme (+). The bottom panel shows 
quantiﬁ   cation of the McrBC-sensitive (methylated) 
DNA fraction from the samples shown in the top 
panel. (E) HPLC quantiﬁ  cation of global 5-methyl-2′-
deoxycytidine (mdC) content. Bars and error bars rep-
resent mean values and SEM from ﬁ  ve measurements, 
respectively, except for HCT116 parental cells and 
MT1KO cells treated with DNMT1 siRNA for 12 d (six 
and two measurements, respectively).JCB • VOLUME 176 • NUMBER 5 • 2007  570
a hypomorphic allele with a null allele resulted in severe 
hypomethy  lation, growth defects, and cancer (Gaudet et al., 
2003). Analogously, the contrasting results previously obtained 
with DNMT1 knockdown experiments in human cell lines are 
likely caused by the varying effi  ciency of RNAi that may or 
may not lower DNMT1 below the threshold level that is suffi  -
cient for the maintenance of normal methylation levels. Also, 
the reduced proliferation rate and viability of severely hypo-
methylated cells may lead to an enrichment of cells with less ef-
fi  cient knockdown of DNMT1, which may explain the variable 
results obtained in different RNAi studies. The drastically de-
creased viability of MT1KO cells that we observed upon the 
knockdown of DNMT1 is also consistent with the rapid cell 
death of mouse fi  broblasts after the conditional KO of Dnmt1 
(Jackson-Grusby et al., 2001). While this manuscript was in 
preparation, a residual DNMT1 activity crucial for cell survival 
was independently identifi  ed in MT1KO cells (Egger et al., 
2006). These results indicate that DNMT1 plays a similar and 
prominent role in the maintenance of DNA methylation in 
mouse and human cells and that the dependence on DNMT1 for 
the survival of differentiated cells is similar in these species and 
likely in all mammals.
We showed that the DNMT1
∆E3–6 mutant expressed in 
MT1KO cells is enzymatically active and displays only a two-
fold reduced postreplicative methylation rate in vivo despite 
lacking the domain responsible for interaction with PCNA. We 
also showed by RNAi-mediated knockdown experiments that 
the expression level of this truncated DNMT1 is critical for the 
maintenance of genomic methylation. Collectively, these results 
demonstrate that the interaction of DNMT1 with the replication 
machinery is not strictly necessary for the maintenance of DNA 
methylation but improves its effi  ciency. As most cell types ex-
press an excess of DNMT1, this improved effi  ciency may not be 
critical for cell survival but may contribute to the faithful main-
tenance of epigenetic information and stable gene expression 
patterns in differentiated cells and developing organisms.
Materials and methods
Cell culture and transfection
HeLa, HEK293T, and HCT116 cells and their derivatives were maintained in 
DME supplemented with 10% FBS, 2 mM L-glutamine, and 50 μg/ml genta-
mycine. All HCT116 cell lines were supplied by B. Vogelstein and K. Schuebel 
(Johns Hopkins University, Baltimore, MD). Cells were transfected with Trans-
fectin (Bio-Rad Laboratories) according to the manufacturer’s instructions.
Northern blotting and RT-PCR analysis
5 μg poly (A)
+ RNA from the indicated cell lines were subjected to North-
ern blotting and probed with a 1.1-kb BamHI fragment from DNMT1 cDNA 
according to standard procedures. For RT-PCR, total RNA was isolated form 
HCT116, MT1KO, and DKO cells with TRIzol reagent (Invitrogen), and 
reverse transcription was performed with the First Strand cDNA Synthesis kit 
(GE Healthcare) by priming with random hexamer oligonucleotides. PCR 
ampliﬁ  cations were performed in a 50-μl ﬁ  nal volume containing 1.5–2.0 
U SAWADY Taq DNA polymerase (PeqLab), 1× buffer (20 mM Tris, pH 
8.55, 16 mM [NH4]2SO4, 2 mM MgCl2, and 0.1% Tween 20), 0.2 μM of 
each primer, and 0.2 mM of each deoxynucleotide triphosphate. For pri-
mary PCR reactions, cDNA template from  0.75 μg of total RNA was used 
with either primers HMT1catF (5′-T  G  C  A  A  C  A  T  C  C  T  G  C  T  G  A  A  G  C  T  G  G  -3′; 
forward, exon 32) and HMT1catR (5′-G  A  C  C  C  G  A  G  C  T  C  A  A  C  C  T  G  G  T  T  A  T  G  -3′; 
reverse, exon 35) or HMT1mF (5′-G  T  C  T  G  C  T  G  A  A  G  C  C  T  C  C  G  A  G  A  T  G  -3′; 
forward, exon 1) and HMT1e15R (5′-T  T  T  G  A  G  G  T  C  A  G  G  G  T  C  G  T  C  C  A  G  G  -3′; 
reverse, exon 15) as well as the following touchdown cycling proﬁ  le: 
94°C for 2 min; 10 cycles at 94°C for 20 s; 68–60°C descending by 2°C 
every two cycles for 15 s; 72°C for 30 s plus a 3-s increment at each cycle; 
30 cycles at 94°C for 20 s; 58°C for 15 s; and 72°C for 1 min plus a 5-s 
increment at each cycle. For nested PCR reactions, 1 μl of primary reaction 
product was used as a template with primers HMT1e2F (5′-A  A  A  G  A  T  T  T-
G  G  A  A  A  G  A  G  A  C  A  G  C  T  T  A  A  C  A  G  -3′; forward, exon 2) and HMT1e10R 
(5′-T  C  T  C  C  A  T  C  T  T  C  G  T  C  C  T  C  G  T  C  A  G  -3′; reverse, exon 10) and a cycling 
proﬁ  le consisting of 25 cycles of 94°C for 20 s, 58°C for 15 s, and 72°C 
for 30 s plus a 5-s increment at each cycle.
Antibodies
Monoclonal antibodies were raised against puriﬁ  ed recombinant DNMT1 
and 6×His-tagged PCNA. Approximately 50 μg of antigen was injected 
both i.p. and subcutaneously into Lou/C rats using CPG2006 (TIB MOL-
BIOL) as adjuvant. After an 8-wk interval, a boost was given i.p and subcu-
taneously 3 d before fusion. Fusion of the myeloma cell line P3X63-Ag8.653 
with the rat immune spleen cells was performed according to standard 
  procedures. DNMT3B was detected with a mouse monoclonal antibody that 
recognizes the conserved catalytic domain within the DNMT3 family (clone 
64B1446; Imgenex). The lamin B1 (H90), β-actin (clone AC-15), and GFP 
antibodies were obtained from Santa Cruz Biotechnology, Inc., Sigma-Aldrich, 
and Roche, respectively.
Plasmid construction
Expression constructs for mouse GFP-Dnmt1
∆PBD, GFP-Dnmt1
C1229W, human 
GFP-DNMT1
wt, and RFP-PCNA were described previously (Easwaran 
et al., 2004; Schermelleh et al., 2005; Sporbert et al., 2005). The GFP-
DNMT1
∆E3–6 expression construct was derived from the GFP-DNMT1
wt con-
struct by overlap extension PCR (Ho et al., 1989).
Coimmunoprecipitation and DNMT assay
Extracts were prepared from transfected HEK293T cells in lysis buffer (20 mM 
Tris-HCl, pH 7.5, 150 mM NaCl, 0.5 mM EDTA, 2 mM PMSF, and 
0.5% NP-40), diluted with lysis buffer without NP-40, and incubated with 
an anti-GFP antibody for 30 min at 4°C with constant mixing. Immuno-
complexes were pulled down with protein A–Sepharose beads (GE Health-
care), and the beads were washed extensively with dilution buffer 
containing 300 mM NaCl. For coimmunoprecipitation, beads were resus-
pended in SDS-PAGE loading buffer. For in vitro methyltransferase assay, 
beads were further washed with and resuspended in assay buffer (100 mM 
KCl, 10 mM Tris, pH 7.6, 1 mM EDTA, and 1 mM DTT), and 30 μl methyl-
ation mix (0.1 μCi [
3H]S-adenosyl-methionine, 1.67 pmol/μl hemimethyl-
ated double-stranded 35-mer oligonucleotide, and 160 ng/μl BSA in 
assay buffer) was added. After incubation at 37°C for 2.5 h, reactions 
were spotted onto DE81 cellulose paper ﬁ  lters (Whatman), and radioactivity 
was measured by liquid scintillation.
Live cell trapping assay
The DNMT trapping assay was performed essentially as described previ-
ously (Schermelleh et al., 2005). In brief, transfected cells were incubated 
with 30 μM 5-aza-dC (Sigma-Aldrich) for the indicated periods of time 
before photobleaching experiments. FRAP analysis was performed with a 
confocal laser-scanning microscope (TCS SP2; Leica) equipped with a 
63× 1.4 NA plan-Apochromat oil immersion objective (Leica). GFP and 
RFP were excited with a 488-nm Ar laser and a 561-nm diode laser, 
  respectively. Image series were recorded with a frame size of 256 × 256 
pixels, a pixel size of 100 nm, and laser power set to 1–5% of transmission 
with a detection pinhole size of 1 Airy U. For FRAP analysis, regions of in-
terest were photobleached with an intense Ar laser beam (laser set to maxi-
mum power at 100% transmission of all laser lines) for 0.5 s. Image series 
were recorded before and after bleaching at 0.27-s intervals (typically 20 
prebleach and 50–100 postbleach frames). Mean ﬂ  uorescence intensities 
of the bleached region were corrected for background and total loss of 
nuclear ﬂ   uorescence over the time course and were normalized to the 
mean of the last 10 prebleach values.
RNAi
Equal numbers of MT1KO cells were plated and transfected the next day 
(day 0) and every second day with 40 nM of either DNMT1 ShortCut 
siRNA Mix (New England Biolabs, Inc.) or a control siRNA (AllStars Nega-
tive Control siRNA; QIAGEN) using HiPerFect transfection reagent (QIAGEN). 
On days 2, 4, and 8, cells were harvested, aliquots were collected 
for protein extracts and DNA isolation, and equal numbers were replated 
and simultaneously transfected. On days 6 and 10, cells were transfected 
without splitting. The medium was never changed in between transfections.MAINTENANCE OF DNA METHYLATION IN HUMAN CELLS • SPADA ET AL. 571
Global genomic methylation analysis
Genomic DNA was isolated by the phenol-chloroform extraction method. 
For the McrBC nuclease assay, 0.5-μg aliquots were incubated with or 
without 10 U of the enzyme (New England Biolabs, Inc.) in buffer supplied 
by the manufacturer for 1 h at 37°C, and digests were separated by aga-
rose gel electrophoresis. ImageJ software (http://rsb.info.nih.gov/ij/) was 
used to quantify the McrBC-resistant fractions from digital images. The 
McrBC-sensitive fraction shown in Fig. 3 D was calculated as follows: 
  (resistant fraction − mock-resistant fraction)/mock-resistant fraction. For 
HPLC analysis, DNA samples were further treated with RNase A and T1, 
phenol extracted, dialyzed extensively against 10 mM Tris, pH 7.2, and 
0.1 mM EDTA, and hydrolyzed to nucleosides as described previously 
(Song et al., 2005) except that 5 U Antarctic phosphatase (New England 
Biolabs, Inc.) was used for dephosphorylation. HPLC was performed on 
the Alliance system (Waters) using a Nucleosil C-18 column at a ﬂ  ow rate 
of 0.5 ml/min with a linear increase of buffer A (0.1 M HNEt3OAc) from 
0 to 20% in buffer B (0.1 M HNEt3OAc in 80% acetonitrile) in 30 min.
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